Table 3.
Inflammatory bowel disease management and clinical outcomes following immune checkpoint inhibitor treatment stratified by prevalence of inflammatory bowel disease exacerbation
|
|
Exacerbation
|
No exacerbation
|
P
value1
|
|
n
= 7
|
n
= 12
|
||
| Follow up time, d, median, IQR | 435, 306 | 572, 450 | 0.4824 |
| Length of ICI use, mo, median, IQR | 12, 10 | 6.5, 9.3 | 0.3685 |
| Reason for ICI discontinuation, n (%) | |||
| Cancer remission | 1 (14.3) | 1 (8.3) | 1.0000 |
| Cancer non-response | 0 (0) | 2 (16.7) | 0.5088 |
| Side effect(s) | 1 (14.3) | 3 (25.0) | 1.0000 |
| Patient preference | 0 (0) | 1 (8.3) | 1.0000 |
| Deceased | 1 (14.3) | 2 (16.7) | 1.0000 |
| Unknown | 0 (0) | 1 (8.3) | 1.0000 |
| Not discontinued | 4 (57.1) | 2 (16.7) | 0.1287 |
| GI-related hospitalization, n (%) | 4 (57.1) | 0 (0) | 0.0090 |
| GI-related surgery, n (%) | 2 (28.6) | 0 (0) | 0.1228 |
| IBD medications used after ICI initiation, n (%) | |||
| Aminosalicylates | 4 (57.1) | 4 (33.3) | 0.3765 |
| Glucocorticoids | 3 (42.9) | 4 (33.3) | 1.0000 |
| TNF inhibitor | 2 (28.6) | 1 (8.3) | 0.5232 |
| Mercaptopurine | 1 (14.3) | 0 (0) | 0.3684 |
| None | 2 (28.6) | 5 (41.7) | 0.6562 |
| Deceased, n (%) | 1 (14.3) | 4 (33.3) | 0.6027 |
1
P-values from Fisher's exact test.
IQR: Interquartile range; IBD: Inflammatory bowel disease; ICI: Immune checkpoint inhibitor; GI: Gastrointestinal; TNF: Tumor necrosis factor.